After a mere two weeks, behold the fairer, younger-looking you
Contact us Mail us at [email protected] Request a sample quote Schedule a consultation Dont just participate in the anti-aging market lead it
You need the precision of Mod GRF 1-29
Side-by-Side Comparison Feature Structure Melanotan 2 Cyclic 7-amino acid peptide Afamelanotide (MT-I) Linear 13-amino acid peptide PT-141 (Bremelanotide) Cyclic 7-amino acid derivative Feature Receptor focus Melanotan 2 MC1R + MC3R + MC4R + MC5R (non-selective) Afamelanotide (MT-I) MC1R-preferring PT-141 (Bremelanotide) MC3R/MC4R-preferring Feature Plasma half-life Melanotan 2 ~1-2 hours Afamelanotide (MT-I) ~0.8-1.7 hours PT-141 (Bremelanotide) ~2.7 hours Feature Main effect Melanotan 2 Tanning + sexual + appetite changes Afamelanotide (MT-I) Tanning and photoprotection PT-141 (Bremelanotide) Sexual arousal and desire Feature Tanning strength Melanotan 2 Strong Afamelanotide (MT-I) Strong PT-141 (Bremelanotide) Minimal Feature Sexual effect Melanotan 2 Strong in ED studies Afamelanotide (MT-I) Not primary PT-141 (Bremelanotide) Primary use case Feature Dosing Melanotan 2 Daily loading, then 1-2x weekly Afamelanotide (MT-I) Subcutaneous implant PT-141 (Bremelanotide) On-demand, max 1 per 24 hours Feature FDA status Melanotan 2 Not approved Afamelanotide (MT-I) Approved (Scenesse) for EPP PT-141 (Bremelanotide) Approved (Vyleesi) for low female sexual desire Feature Nausea burden Melanotan 2 High and dose-limiting Afamelanotide (MT-I) Lower in selective use PT-141 (Bremelanotide) Common, listed on label These three compounds share melanocortin ancestry, but they are not interchangeable
Haematologica 96 (11), 17081711
These agents mainly include those that inhibit SASP-related signaling pathways, regulate epigenetic modifications, enhance autophagy, improve mitochondrial function, etc
